Breast Biopsy Marker Market

Breast Biopsy Marker Market Outlook (2022-2032)

The global breast biopsy marker market has reached a valuation of US$ 798 million in 2022 and is predicted to expand at a healthy CAGR of 5.8% to end up with a market size of more than US$ 1.4 billion by 2032.

Sales of breast biopsy markers are directly reliant on the number of breast cancers and breast biopsies performed, in which South Asia and ASEAN is the leading market at present.

Report Attributes	Details
Breast Biopsy Marker Market Size (2021A)	US$ 755.7 Million
Estimated Market Value (2022E)	US$ 798 Million
Forecasted Market Value (2032F)	US$ 1.4 Billion
Global Market Growth Rate (2022-2032)	5.8% CAGR
North America Market Share (2021)	~ 17.2%
South Asia and ASEAN Market Growth Rate (2022-2032)	~ 5.2% CAGR
United States Market Growth Rate (2022-2032)	~ 6.5% CAGR
Market Share of Top 5 Companies	~ 64.6%
Key Companies Profiled	Hologic Carbon Medical Technology BD Mermaid Medical Argon Medical Devices INRAD Cortex Cook Medical Scion Medical Technologies

Sales Analysis of Breast Biopsy Markers (2017-2021) Vs. Market Forecasts (2022-2032)

Globally, breast cancer is considered the most common invasive cancer among women. Breast biopsies are used for diagnosis and treatment planning purposes.

To identify the biopsy site, breast biopsy site markers, which are made of surgical-grade materials, are placed inside the tissue after the completion of the biopsy process. These biopsy markers are visible under various image guidance technologies (MRI, ultrasound, etc.) that point out the exact location of the biopsy site.

The combined use of titanium and stainless steel breast biopsy markers has increased by a compound annual growth rate of 5.4% from 2017 to 2021, which has greatly influenced the sales of breast biopsy markers across regions. Rise in the number of breast lesions among the female population has increased timely breast screening diagnosis, which acts as a key driver for breast biopsy marker market growth.

The availability of better biocompatible and affordable biopsy markers is driving several key players to manufacture titanium breast biopsy markers that will directly accelerate the growth of the market over the forecast period.

Fact.MR suggests that the global breast biopsy marker market will be valued at US$ 1.4 billion by 2032-end, expanding at a CAGR of 5.8% over the decade.

• Short Term (2022 Q2 to 2025): Enhancing use and integration of breast biopsy markers in early cancer diagnosis to favorably affect market growth.
• Medium Term (2025-2028): Introduction of advanced minimally-invasive and best-in-class tumor markers and localization solutions for breast biopsy to propel market growth.
• Long Term (2028-2032): Entrance of leading global healthcare sector manufacturers will dictate the long-term growth of the market across regions.

Between 2017 and 2021, the global breast biopsy marker market registered a CAGR of 5.4%, and according to Fact.MR, a market research and competitive intelligence provider, it is projected to expand at 5.8% CAGR between 2022 and 2032.

Market share analysis of breast biopsy markers based on coating type and region. Under the coating type segment, the without coating segment currently dominates with 89.3% market share.

Why is There Healthy Demand Growth for Breast Biopsy Markers?

“Rising Incidence of Breast Cancer Driving Sales of Breast Biopsy Markers”

Breast cancer is known to be amongst the most prevalent anomaly worldwide. According to the American Cancer Society, breast cancer is the second-leading cause of cancer-related deaths among the population. It was observed that, in the year 2018, over 265,000 new cases of breast cancer were detected among women and one in every eight women was likely to be diagnosed with breast carcinoma.

Breast biopsy markers are used in the biopsy process that offers the advantage of identifying and marking the biopsy area with a physical tag that helps the surgeon in the diagnosis and operating process. Therefore, a rise in the number of breast cancer patients across the world is likely to uplift the breast biopsy marker market in parallel.

“Government Initiatives in Breast Cancer Screening to Maintain Market Growth Trajectory”

To reduce global breast cancer deaths, which are rising due to late-stage diagnosis and inadequate access to quality care, various organizations and governments are introducing initiatives and healthcare programs with the idea of promoting an integrated approach towards breast cancers more broadly.

• For instance, in May 2021, WHO announced a program titled 'Global Breast Cancer Initiative' to bring down the global breast cancer mortality rates by 2.5% every year until 2040.

Timely diagnosis and supportive care during treatment help make a substantial progress through these initiatives. Regular check-ups for breast cancers are done by performing biopsies that make use of breast tissue markers for identification of the biopsy site.

Early investigation provided by such programs will boost the usage of breast tissue markers, which will ultimately drive market growth.

How Can Market Expansion Be Dented to Some Extent?

“Exorbitant Rates of Breast Biopsy Markers Making Them Unaffordable for Cancer Patients”

Breast biopsy markers are developed and distributed as per approvals from regulatory agencies such as the U.S. FDA and others. To obtain clearance for their products, manufacturers need to submit comprehensive clinical data that supports the safety and efficacy of the product on trial. These approval processes are usually lengthy and also involve a lot of investments, which directly affects the pricing of the product.

High cost of production also affects the final price of the product. Hence, financial toxicity that represents a considerable economic burden on breast biopsy patients acts as a restraining factor for market progress.

Country-wise Insights

Will Rise in Breast Biopsies in South Asia & ASEAN Drive Regional Market Growth?

The breast biopsy marker market in South Asia & ASEAN is expected to expand at a CAGR of 5.2% and reach a valuation of US$ 320.3 million by 2032.

In the last few years, the prevalence of breast cancer has rapidly increased in Asian populations. As per research, in India, breast cancer incidence rates have escalated by 30%, and in Singapore, the rates have doubled in the last few years.

With this dramatic increase in breast cancer among the population, over the coming years, a majority of breast cancer patients worldwide would be of Asian origin.

Rising interest in R&D as well as the introduction of various awareness programs by breast cancer researchers across regions has the potential to accelerate advancements in the treatment of patients on a regional and global level.

For instance, in Malaysia, the proportion of stage III and stage IV breast cancer was considerably reduced due to the introduction of clinical breast examinations across rural as well as urban districts. With such initiatives for breast cancer screening, breast biopsy surgeries will increase, which will directly uplift the market for breast biopsy markers in the South Asia & ASEAN region.

Which Countries are Highly Lucrative Markets in Europe?

The European market accounted for 22.7% share of the global breast biopsy marker market at the end of 2021.

Europe enjoys modernization and digitalization of health systems and infrastructure, which presents a significant market opportunity for breast biopsy marker suppliers. Government initiatives and health insurance policies are anticipated to boost the market in the region, especially in the U.K. Germany, and Italy.

• For instance, in Italy, the National Health Service with regional bases provides universal coverage, which is mostly free of charge at the point of service.

National and local taxes serve as the primary funding source, with copayments for prescription drugs and outpatient care as a complement. In general, every citizen is covered by the national healthcare system and there are free services from government-employed doctors, which creates a highly lucrative and affordable market for breast biopsy markers.

The U.K, Germany, and Italy markets for breast biopsy markers are expected to grow at CAGRs of 5.9%, 5.6%, and 7.2%, respectively, over 2022 to 2032.

Category-wise Insights

Which Material is Most Widely Used in Making Breast Biopsy Markers?

The breast biopsy marker, under material type, is categorized into metals & alloys and non-metals. Amongst them, titanium, a biocompatible material that comes under the metals & alloys segment, held a high market share of 31.4% in 2021 and is expected to exhibit a CAGR of 5.5% through 2032.

The market for titanium breast biopsy markers is seeing tremendous growth as a result of rising demand by the end users (hospitals, specialty clinics, ASCs, etc.) that perform breast biopsies on a large scale. Although many commercial markers made from other materials are available in the market, they are relatively expensive, which becomes a burden on the patients who are in need.

Thus titanium, a cheaper biocompatible alternative that is widely available, is most used by healthcare providers.

Why is Demand for Bioabsorbable Breast Biopsy Markers Surging?

Due to advancements in technologies to produce cost-effective biomarkers by using biodegradable materials, breast biopsy markers with bioabsorbable coatings are predicted to upscale the market over the coming years.

Use of bioabsorbable coating breast biopsy markers is projected to grow over the forecast period at a high CAGR of 7.2%.

Competitive Landscape

Prominent breast biopsy marker manufacturers are Hologic, Carbon medical technology, BD, Mermaid Medical, and Argon Medical Devices.

Top manufacturers of breast biopsy markers are using revolutionary technologies and optimization. Leading manufacturers are concentrating on creating new products with enhanced imaging capabilities and biocompatibility.

• In May 2019, Argon Medical Devices, a global medical device manufacturer, completed the acquisition of Mana-Tech Ltd, a distributor of medical biopsy equipment in the U.K. and Ireland. This acquisition would allow them to commercialize their products across Europe.
• In Jan 2021, Hologic, Inc. completed the acquisition of Somatex Medical Technologies, a leading biopsy site marker and localization technology manufacturer.

Fact.MR has provided detailed information about the price points of key manufacturers of breast biopsy markers positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.

Segmentation of Breast Biopsy Marker Industry Research

• By Coating Type :

  • With Bio-Absorbable Coating
  • Without Coating

• By Material :

  • Metals & Alloys
    • Titanium
    • Stainless Steel
    • Nitinol
    • Nickel-Chromium
    • Others
  • Non-Metals
    • Carbon-coated Ceramic
    • Carbon-coated Zirconium Oxide
    • PEKK

• By Provider :

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgery Centers

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & ASEAN
  • Oceania
  • MEA